Israel’s PolyPid Revives $80 Million NASDAQ IPO Plan



Israel’s PolyPid, which develops an antibiotic coating for bone repair, is reinitiating plans for an IPO. It hopes to raise $18 – $22 million for a company valuation of as much as $80 million.

After first disclosing plans for a NASDAQ IPO in July 2014, PolyPid put those plans on hold last October. At the time the company attributed the delay to a poor environment in general for IPOs, but that it would try again sometime in 2015.

Aegis Capital will be the chief underwriter, with Chardan Capital and MLV & Co. as secondary underwriters.

Based in Petah Tikva, Israel, PolyPid describes itself as an emerging clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), is proprietary drug delivery technology. The company boasts that PLEX is able to securely encapsulate many types of drugs, including proteins, to enable targeted, localized drug delivery into the body over periods of time ranging from days to several months.

The PLEXTM platform is a matrix made of thousands of alternating layers of polymers and lipids that entrap a therapeutic drug between them in order to form a protected reservoir that enables an effective localized drug delivery in the body. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months. The application of our PLEX technology in our products enables us to optimize drug treatment regimens by predetermining release rates and durations, a rare combination of attributes.

PolyPid also has two lead candidates for use with bone transplants, BonyPid-1000 and BonyPid-500.

BonyPid-1000 is a bone graft substitute based product intended for filling bone voids or defects. It resorbs and is replaced with bone during the healing process.

BonyPid-500 is intended for use as a bone grafting material to fill, augment or reconstruct periodontal or oral/maxillofacial defect, such as filling of periodontal/infrabony defects, ridge augmentation, filling of extraction sites, sinus lifts and filling of cystic cavities.

It is currently planning to hold clinical trials in the U.S and Canada next year and hopes to be able to market its products in Europe in 2017.

PolyPid plans to be listed on the NASDAQ under the symbol PLPD. It first filed confidentially on July 8, 2014.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.